Tarveda Therapeutics (Fomerly Known As Blend Therapeutics)

66 articles about Tarveda Therapeutics (Fomerly Known As Blend Therapeutics)

• 

  Clinical Catch-Up for September 31-October 4

  10/7/2019

  It was another busy week for clinical trials. Here’s a look.

• Tarveda Therapeutics Presents Data from the Phase 1 Portion of a Phase 1/2a Study of PEN-866 at the European Society for Medical Oncology (ESMO) Congress 2019

  9/30/2019

  Preliminary evidence of tolerability and anti-tumor activity, and Maximum Tolerated Dose (MTD) established

• Tarveda Therapeutics to Present at Upcoming Conferences

  9/23/2019

  Tarveda Therapeutics®, Inc., today announced that the company will present results from the Phase 1 portion of a Phase 1/2a study of PEN-866 in patients with advanced solid malignancies at the European Society for Medical Oncology (ESMO) Congress 2019,

• Tarveda Therapeutics to Present at Raymond James Life Sciences and MedTech Conference

  6/11/2019

  Tarveda Therapeutics®, Inc. announced that Drew Fromkin, President and Chief Executive Officer, will present at the Raymond James Life Sciences and MedTech Conference occurring June 18-19, 2019 in New York City.

• Tarveda Therapeutics Announces Presentation at 2019 BIO International Convention

  5/30/2019

  Tarveda Therapeutics®, Inc. announced that Drew Fromkin, President and Chief Executive Officer, will present at the 2019 BIO International Convention occurring June 3-6, 2019 in Philadelphia, PA.

• Tarveda Therapeutics to Present at Needham & Company’s 18th Annual Healthcare Conference

  4/3/2019

  Tarveda Therapeutics, Inc., a clinical stage biopharmaceutical company discovering and developing a new class of potent and selective miniature drug conjugates (Pentarins®) for the treatment of patients with a wide range of solid tumors, today announced that Drew Fromkin, President and Chief Executive Officer, will present at Needham & Company’s 18th Annual Healthcare Conference

• Tarveda Therapeutics to Present Nonclinical Data on PEN-221 in Combination with Epigenetic Modulation at the 2019 AACR Annual Meeting

  3/26/2019

  Data demonstrate how an HDAC inhibitor increases the tumor expression of SSTR2 with synergy of efficacy

• Tarveda Therapeutics to Present at Cowen and Company 39th Annual Health Care Conference

  3/4/2019

  Tarveda Therapeutics, Inc. announced that Drew Fromkin, President and Chief Executive Officer, will present at Cowen’s 39th Annual Health Care Conference, occurring March 11-13, 2019 in Boston, MA.

• Tarveda Therapeutics to Present at the 2019 BIO CEO & Investor Conference

  2/4/2019

  Drew Fromkin, President and Chief Executive Officer, will present at the 2019 BIO CEO & Investor Conference, occurring February 11-12, 2019 at the New York Marriot Marquis.

• Tarveda Therapeutics Provides Year-End Update

  1/4/2019

  Data expected from the PEN-221 Phase 2a trial and PEN-866 Phase 1 dose escalation and safety trial in 2019

• Tarveda Therapeutics to Present at the 2019 Biotech Showcase

  1/3/2019

  Tarveda Therapeutics, a clinical stage biopharmaceutical company discovering and developing a new class of potent and selective miniature drug conjugates (Pentarins®) for the treatment of patients with a wide range of solid tumors today announced that Drew Fromkin, President and Chief Executive Officer, will present at the 11th Annual Biotech Showcase, occurring January 7-9, 2019 at the Hilton Union Square in San Francisco.

• Tarveda Therapeutics to Present at EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium

  11/8/2018

  Data presented explores kinase inhibitor targeting approach using HSP90 binding conjugate platform

• Tarveda Therapeutics to Present at Cantor Fitzgerald 2018 Global Healthcare Conference

  9/26/2018

  Tarveda Therapeutics, Inc., announced that Drew Fromkin, President and Chief Executive Officer, will present at the Cantor Fitzgerald 2018 Global Healthcare Conference, occurring October 1-3, 2018 in New York City.

• 

  Movers and Shakers for Sept. 17

  9/17/2018

  Let's take a look at some of the professionals moving to transition the pharma and biotech world this past week.

• Tarveda Therapeutics Appoints Jeffrey Bloss, M.D. as Chief Medical Officer

  9/12/2018

  Steven Hamburger, Ph.D. appointed as Vice President, Regulatory Affairs and Laura Mei appointed as Vice President, Clinical Operations.

• Tarveda Therapeutics Announces Results from Phase 1 Study of PEN-221 Presented at the 2018 American Society for Clinical Oncology (ASCO) Annual Meeting

  6/4/2018

  Evidence of antitumor activity observed

• Tarveda Therapeutics to Present at Jefferies 2018 Global Healthcare Conference

  5/31/2018

  Tarveda Therapeutics, Inc. announced that Drew Fromkin, President and Chief Executive Officer, will present at the Jefferies 2018 Global Healthcare Conference.

• Tarveda Therapeutics to Present at 2018 BIO International Convention

  5/29/2018

  Tarveda Therapeutics, Inc. today announced that Drew Fromkin, President and Chief Executive Officer, will present at the 2018 BIO International Convention.

• Tarveda Therapeutics Announces Dosing of First Patient in Phase 1/2a Study of PEN-866 for Patients with Solid Malignancies

  4/24/2018

  Phase 2a trial of PEN-221 has initiated

• Tarveda Therapeutics Presents Data Exploring the Efficacy of PEN-866 in Combination with PARP Inhibitors in Preclinical Models of Human Cancer at the AACR Annual Meeting 2018

  4/18/2018

  Tarveda Therapeutics, Inc., a clinical stage biopharmaceutical company discovering and developing Pentarins™ as a new class of potent and selective cancer medicines, today presented data on the efficacy of PEN-866